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Objectives: We implemented the WHO cross-sectional survey protocol to determine rates of HIV viral load (VL)
suppression (VLS), and weighted prevalence, predictors and patterns of acquired drug resistance (ADR) in individ-
uals with virological failure (VF) defined as VL1000 copies/mL.
Methods: We enrolled 547 and 1064 adult participants on first-line ART for 12 (±3) months (ADR12) and
48 months (ADR48), respectively. Dried blood spots and plasma specimens were collected for VL testing and
genotyping among the VFs.
Results: VLS was 95.0% (95% CI 93.4%–96.5%) in the ADR12 group and 87.9% (95% CI 85.0%–90.9%) in the
ADR48 group. The weighted prevalence of ADR was 96.1% (95% CI 72.9%–99.6%) in the ADR12 and 90.4% (95%
CI 73.6–96.8%) in the ADR48 group, out of the 30 and 95 successful genotypes in the respective groups.
Initiation on a zidovudine-based regimen compared with a tenofovir-based regimen was significantly associated
with VF in the ADR48 group; adjusted OR (AOR) 1.96 (95% CI 1.13–3.39). Independent predictors of ADR in the
ADR48 group were initiation on a zidovudine-based regimen compared with tenofovir-based regimens, AOR 3.16
(95% CI 1.34–7.46) and ART duration of82 months compared with <82 months, AOR 1.92 (95% CI 1.03–3.59).
Conclusions: While good VLS was observed, the high prevalence of ADR among the VFs before they underwent
the recommended three intensive adherence counselling (IAC) sessions followed by repeat VL testing implies
that IAC prior to treatment switching may be of limited benefit in improving VLS.
Introduction
The Joint United Nations Programme on HIV/AIDS (UNAIDS) set up
the 90–90–90 targets that aim to have 90% of people living with
HIV knowing their status, 90% of these on ART and 90% of those
on ART virally suppressed.1 The ART programmes in resource-
limited settings are characterized by the use of limited antiretro-
viral regimens and often limited use of viral load (VL) testing
to monitor treatment outcomes and to maximize the long-term
effectiveness of ART. To ensure sustainability of ART programmes,
the WHO has recommended HIV drug resistance (HIVDR)
monitoring and surveillance.2 Even in settings with optimal ART
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programme management, some degree of HIVDR is expected
to emerge in populations receiving ART, which could affect the
response to ART, as well as be a source of HIVDR transmission.
In the WHO HIVDR monitoring and surveillance strategy,
surveillance of HIVDR in adult populations both initiating3 and
receiving ART4 has been recommended, with guidance for similar
surveillance in children. HIVDR surveillance in nationally represen-
tative populations initiating first-line ART regimens is essential
to inform the selection of first-line ART combinations, while surveil-
lance of HIVDR in populations receiving first-line ART is critical to
assess ART programme quality and inform the selection of
second-line ART regimens. Suboptimal VL suppression (VLS) and
the detection of HIVDR in populations receiving ART may reflect
gaps in ART programme quality, including inadequate adherence
assessment and support, interruptions in drug supply and low
retention in care.
The earliest surveys conducted in Uganda indicated that the
prevalence of HIVDR varied across populations: <5% for transmit-
ted drug resistance among pregnant women in Entebbe;5 2.6%
among sex workers in Kampala;6 1.4% in a rural population;7 6%
among individuals with recent HIV infection in Masaka and
Entebbe;8 and 8.6% among young adults in Kampala.9 There are a
few studies conducted for pre-treatment and acquired HIVDR
(ADR) among adults in sub-Saharan Africa; in one multicentre
study in five African countries including three sites in Uganda, the
pooled pre-treatment/baseline HIVDR prevalence for Ugandan
sites was 11.6%.10 In another prospective survey conducted
among 420 adults in Uganda from 2012 to 2013, the baseline
prevalence of HIVDR was 4.9% and increased to 9.0% after
12 months of ART.11 Another study reported HIVDR prevalence of
7% after 6 months of ART in a cohort of 325 patients in central
Uganda.12 A recent meta-analysis has shown a substantial in-
crease of pre-treatment NNRTI drug resistance in low- and
middle-income countries especially in sub-Saharan Africa,13 while
another study in Uganda showed an increasing prevalence of pre-
treatment drug resistance in women but not among men in the
period between 2005 and 2013.14 In this report, we present find-
ings using the WHO cross-sectional survey protocol of HIVDR
among adults receiving ART.4 We report levels of VLS among adult
patients on first-line ART for 12 (±3) and 48 months, and we
determined the predictors of virological failure (VF; defined as VL
1000 copies/mL) and the weighted prevalence and patterns of
ADR mutations in patients with VF.
Methods
Study setting and participants
This survey was designed and the analyses conducted following the WHO
methods for surveillance of HIVDR in adults receiving ART.4 This was a
cross-sectional survey conducted using a two-stage cluster design among
adult (18 years) populations receiving ART for 12 (±3) months (ADR12) at
23 out of the 24 selected sites; and among those receiving ART for at least
48 months (ADR48) at the 24 sites. Clinics chosen for the ADR12 survey
were chosen among those that had been dispensing ART for at least
15 months and those chosen for the ADR48 survey were selected among
clinics that had been dispensing ART for at least 48 months. The main
purpose of this survey was to determine a nationally representative preva-
lence estimate with associated confidence intervals of VLS and presence
of HIVDR by genotypic testing among the VFs. We also determined
independent predictors of VF and prevalence and patterns of HIVDR in
these two populations. The study populations included all HIV-infected per-
sons who provided written informed consent. Patients whose date of ART
initiation was unknown were excluded. Eligible participants were enrolled
sequentially until the desired sample size for each site was reached.
Consenting participants were assigned a unique study identifier, and study
variables were abstracted from each patient file.
Site and patient selection for ADR12 and ADR48
The ADR12 survey was conducted in August to November 2016 while the
ADR48 survey was done in September to November 2017. Prior to sampling,
study sites were selected from a list of all clinics in the country dispensing
ART for at least 12 months and 48 months, for the ADR12 and ADR48
surveys, respectively. The smallest sites that made up <10% of the total
population of patients on ART were excluded. The clinics were then strati-
fied into five geographical regions and sites were randomly selected pro-
portionally to the size of the region. Considering the prevalence of VLS of
85% at 12 months and 70% at 48 months, a PCR amplification rate of 80%,
an intracluster correlation coefficient for VLS of 0.8%, a design effect of 1.5
and accounting for dropout, 24 sites with 22 participants and 24 sites with
46 patients from each clinic were chosen for ADR12 and ADR48 surveys,
respectively.
A base weight for each sampled unit was then constructed to correct
for their unequal probability of selection. The base weight was constructed
by taking the reciprocal of its probability of selection into the sample. This
being a two-stage design (sites at the regional level and individuals at the
site level), the base weights reflected probabilities of selection at each
stage.
VL testing and HIVDR genotyping
Venous whole blood was collected for preparation of two dry blood spot
(DBS) cards containing five spots each or two aliquots of plasma speci-
mens15,16 from each patient, with one DBS card or plasma aliquot for VL
testing and the second card or plasma aliquot for genotypic testing. The
DBS specimens were shipped at room temperature from the sites to Central
Public Health Laboratories (CPHLs) using the National Sample and Results
Transport Network17 also used by the Early Infant Diagnosis programme.18
Plasma specimens were transported in liquid nitrogen tanks to CPHLs. VL
testing was done at CPHLs using a DBS-VL protocol using the Abbott
RealTime HIV-1 Assay Kit (Abbott Molecular Diagnostics, Des Plaines, IL,
USA) and plasma using COBASV
R
AmpliPrep/COBASV
R
TaqManV
R
HIV-1 Test,
v2.0 kit (Roche Molecular System, Inc., Pleasanton, CA, USA). All specimens
tested and found with VL 1000 copies/mL were shipped to the MRC/
Uganda Virus Research Institute (UVRI) and London School of Hygiene and
Tropical Medicine (LSHTM) Uganda Research Unit laboratories for genotyp-
ing and analysis for HIVDR mutations (HIVDRMs).
Genotyping of the protease and reverse transcriptase regions of the
HIV-1 pol gene was done using a modified and validated in-house
method11,16 at the MRC/UVRI and LSHTM laboratory, which is a WHO HIVDR
Network designated reference laboratory. The 1300 bp segment of the 50
region of the pol gene was generated by RT–PCR followed by nested PCR
using total nucleic acid extracted from the DBS or nucleic acid from plasma.
The fragment was purified, sequenced using a BigDye Terminator v3.1 cycle
sequencing kit (Life Technologies, Foster City, CA, USA) and analysed on an
ABI Prism 3500 Genetic Analyzer (Life Technologies). A combination of the
Sequencher software (SequencherV
R
version 5.4.1 sequence analysis soft-
ware, Gene Codes Corporation, Ann Arbor, MI, USA; http://www.genecodes.
com) and a customized RECall software program19 was used to edit the
raw sequence data and generate consensus sequences. Drug resistance
mutations (DRMs) were analysed by the Stanford HIVdb Program using the
2009 WHO mutation list.20 For quality control purposes, our laboratory is
enrolled in the Virology Quality Assurance programme and all sequences
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generated in the laboratory are assessed for cross-contamination by phylo-
genetic analysis. Sequences from this study were deposited in GenBank
under accession numbers MK359486 to MK359634.
Data management and statistical methods
The patient data were entered into a Microsoft Access database.
Laboratory data comprising VL and HIVDR results were linked to clinical
data using the patient study identifier. All statistical analyses were per-
formed using STATA version 12 (StataCorp LP, College Station, TX, USA). VF
and HIVDR weighted prevalence rates with 95% CIs were calculated.
Statistical analysis for weighted prevalence of VLS and HIVDR accounted
for the survey design features which included stratification, clustering and
survey weights. Weights accounted for unequal selection probabilities, for
both selection of clinics and selection of patients. Stratification was done to
reduce sampling variation to account for stratification by geographical re-
gion during selection of clinics. Clustering accounted for the two clustering
units (patients and clinics). Survey logistic regression was used to determine
associations between patient characteristics and the outcomes: VF and
HIVDR at the P < 0.05 level of significance. Variables that had a P value
<0.20 in simple analysis were included in the adjusted logistic regression
model. However, age and gender, which are potential confounders, were
added to the models irrespective of their P value at univariate analysis.21
Adjusted ORs (AORs), 95% CIs and P values were calculated. By using the
svyset function, the analysis adjusted for survey weights, clustering and
stratification when generating prevalence rates and ORs.
Ethics
This study was approved by the UVRI Research and Ethics Committee
[UVRI-REC Federal Wide Assurance (FWA) No. 00001354] and the Uganda
National Council for Science and Technology (FWA No. 00001293). The
study was also reviewed in accordance with the CDC human research pro-
tection procedures and determined to be research, but CDC investigators
did not interact with human subjects or have access to identifiable data or
specimens for research purposes. All participants gave their written
informed consent prior to enrolment into the study.
Results
The ADR12 survey
Enrolment profile, and socio-demographic and clinical
characteristics
During the study period, a total of 547 patients were enrolled from
23 of the 24 selected sites distributed across the country (Figure 1)
between August and November 2016. One site was excluded
because they declined to participate in the pre-survey training.
A majority were female (365; 66.7%), with an overall median age
of 34 years (IQR 28–41), median CD4 count at ART initiation of
318 cells/mm3 (IQR 182–450) and 81.9% were on the recom-
mended tenofovir (TDF) ! lamivudine (3TC) ! efavirenz (EFV,
n = 439)/nevirapine (NVP, n = 9) first-line regimen at that time
(Table 1); 39 (7.1%) patients were on TDF, emtricitabine (FTC) and
EFV, and 60 (11.0%) patients were on zidovudine (ZDV), 3TC and
EFV, n = 26 or NVP, n = 34.
HIV VL and DRMs at ADR12
The prevalence of VLS among the 533 patients with VL results was
95.0% (95% CI 93.4%–96.5%) (Figure 1 and Table 2) and the
median VL among the 40 VFs was 4.6 log10 copies/mL (95% CI
4.2–4.8) (Table 1). The overall prevalence of HIVDR was 4.7% (95%
CI 3.3–6.1) as shown in Table 2. However, 28 of the 30 (96.1%;
95% CI 72.9%–99.6%) patients with VL 1000 copies/mL who
were successfully genotyped had at least one DRM. One patient
(1.1%; 95% CI 0.14%–3.6%) had the I85V PI mutation, 23 (90.3%;
95% CI 65.6%–97.9%) had NRTI mutations, 26 (94.1%; 95% CI
74.3%–98.9%) had NNRTI mutations and 22 (89.5%; 95% CI
64.7%–97.5%) had both NRTI and NNRTI mutations (Table 2). No
patient was found with all three drug class mutations. Of the 28
patients with mutations, 82.1% had M184V/I, 75% had K103N/S,
28.6% had K65R mutations, 32% had thymidine analogue muta-
tions (TAMs) and 64.3% of participants had the M184V/I NRTI mu-
tation. Table S1 (available as Supplementary data at JAC Online)
summarizes the mutations among the 28 participants.
Factors associated with VF and HIVDRMs at ADR12
There were no factors found to be significantly associated with VF
and HIVDRMs among patients receiving ART for 12 (± 3) months
(Tables 3 and 4).
The ADR48 survey
Enrolment profile, and socio-demographic and clinical
characteristics
A total of 1110 participants were enrolled; however, one site
with 46 participants was excluded from the analysis following a
protocol violation. This site had enrolled study participants with
prior detectable VL which introduced selection bias, contrary to the
consecutive enrolment process that was defined in the study
protocol. Figure 1 summarizes the profile of the enrolled study par-
ticipants. Among the 1064 participants included in this analysis,
the median age was 44 years (IQR 37–51), median CD4 count at
ART initiation was 214 cells/mm3 (IQR 126–310) and 34.7% of the
participants were males. By the time of survey enrolment, 853
(80.2%) of the patients were maintained on their initial first-line
regimen: TDF!3TC ! EFV (n = 192)/NVP (n = 95) or ZDV!3TC !
EFV (n = 84)/NVP (n = 482) and 211 (19.8%) had their regimen sub-
stituted, including all the 101 who had been initiated on stavudine
(D4T). The median time on ART was 82 months (IQR 78.5–85.0)
(Table 5).
HIV VL and DRMs at ADR48
The prevalence of VLS among all the 1064 patients was 87.9%
(95% CI 85.0–90.9), shown in Figure 1 and Table 6, and the median
VL among the 138 VFs was 3.7 log10 copies/mL (95% CI 3.6–3.9)
(Table 5).
The overall prevalence of HIVDR was 7.6% (95% CI
5.4%–9.5%) as shown in Table 6. However, 88 of the 95 (90.4%;
95% CI 73.6%–96.8%) patients with VL 1000 copies/mL who
were successfully genotyped had at least one DRM (Table 6).
We observed that of the 88 patients that had HIVDR, 84
(86.8%; 95% CI 76.3%–97.3%) had NRTI mutations, 86 (87.6%;
95% CI 76.4%–98.8%) had NNRTI mutations, 82 (81.9%; 95% CI
71.2%–92.6%) had both NRTI and NNRTI mutations while
none had PI mutations. Of the 88 patients with mutations, 82
(93.2%) had MI84V/I, 37 (42.0%) had K103N/S, 24 (27.3%) had
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Y181C and 46 (52.3%) had TAMs. Table S2 summarizes the
mutations among the 88 participants.
Factors associated with VF and HIVDRMs at ADR48
Initiation on a zidovudine-based regimen compared with a
tenofovir-based regimen was significantly associated with VF
among patients receiving ART for at least 48 months (AOR 1.96,
95% CI 1.13–3.39, P = 0.02). There was a weak association be-
tween patients who had been on ART for at least 82 months com-
pared with those who had been on ART for <82 months (AOR 1.77,
95% CI 0.94–3.33 P = 0.07) (Table 7).
Independent predictors for HIVDR among patients receiving
ART for at least 48 months were: ART duration of at least
82 months compared with patients on ART for less than 82 months
(AOR 1.92, 95% CI 1.03–3.59, P = 0.04) and initiating on a
zidovudine-based regimen compared with a tenofovir-based regi-
men (AOR 3.16, 95% CI 1.34–7.46, P = 0.01) (Table 8).
Discussion
To our knowledge, this is the first report highlighting the predictors
of VF, weighted prevalence and patterns of HIVDR among patients
on first-line ART in Uganda using the WHO protocol.
The VLS rates from this survey were very similar to the findings
of a descriptive cross-sectional study conducted in Uganda be-
tween 2014 and 2015 using routinely collected programme data
from VL samples collected across the country that found an overall
VF of 11%.22 In that survey, however, they included all patients on
ART irrespective of age, regimen or duration on ART (for
>6 months) and they defined VF as those with plasma VL 1000
copies/mL or DBS VL 5000 copies/mL, which could have made it
less comparable to the present study. A much earlier survey in
Uganda between 2012 and 2013 that implemented a WHO HIVDR
survey protocol at three treatment centres found VLS at 85% and
ADR at 9% among patients on first-line ART for 12 months and
associated VF with high baseline VL and type of treatment
547 adults on ART for 12 (± 3) months
(a) (b)
1110 adults on ART for ≥ 48 months
1 site excluded for
protocol violation
(n=46; 4.1%)
Viral load done
(n=533; 97.4%)
Viral load done
(n=1064; 95.9%)
Virological failures
(n=138; 13.0%)
Genotyped
(n=95; 68.8%)
Failed Viral Load
(n=14; 2.6%)
Virological suppressors
(n=493; 95.0%)
95% CI: 93.4%-96.5%*
Virological suppressors
(n=926; 87.9%)
95% CI: 85.0%-90.9%*
Failed genotyping
(n=43; 31.2%)Failed genotyping
(n=10; 25%)
28 (93.3%) patients with
HIVDRMs
23 (82.1%) NRTI
26 (92.9%) NNRTI
22 (78.6%) NRTI and
NNRTI
1 (3.6%) PI
None with 3 drug classes
88 (92.6%) patients with
HIVDRMs
84 (95.5%) NRTI
86 (97.7%) NNRTI
81 (92.0%) NRTI and
NNRTI
None with PI
None with 3 drug classes
Virological failures
(n=40; 7.5%)
Genotyped
(n=30; 75%)
Figure 1. Enrolment profiles for ADR12 (August to November 2016) (a) and ADR48 (September to November 2017) (b) surveys of HIV-positive adults
from the selected sites in Uganda. The asterisk indicates weighted analysis.
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Table 1. Demographic, clinical and immunological characteristics of the
547 ADR12 participants in Uganda
Characteristics Total
Gender
male 182 (33.3)
female 365 (66.7)
Age, years, median (IQR) 34 (28–41)
Region
Central 166 (30.3)
East 69 (12.6)
Kampala 34 (6.2)
North 96 (17.6)
West 182 (33.3)
CD4 count at ART initiation, cells/mm3, median (IQR) 318 (182–450)
Viral loada
<1000 copies/mL 493 (92.5)
1000 copies/mL 40 (7.5)
VL among VFs, log10 copies/mL, median (IQR) 4.6 (4.2–4.8)
Time on ART, months, median (IQR) 12.9 (11.2–14.5)
Initial ART regimen
TDF!3TC!EFV/NVP 448 (81.9)
ZDV!3TC!EFV/NVP 60 (11.0)
TDF!FTC!EFV 39 (7.1)
Values are n (%) unless otherwise stated.
aFourteen viral loads did not amplify.
Table 2. Weighted prevalencea of virological suppression and HIVDR
among ADR12 participants
Survey outcome n/N Percentage prevalence (95% CI)
VL suppression
all 493/533 95.0 (93.4–96.5)
male 169/182 97.7 (91.3–99.4)b
female 324/351 93.6 (91.9–95.2)
agec <34 years 267/287 94.8 (91.1–98.5)
age 34 years 225/245 95.1 (91.3–98.9)
HIVDR
any 28/533 4.7 (3.3–6.1)
NRTI 23/533 4.4 (3.1–5.8)
NNRTI 26/533 4.6 (3.3–6.0)
NRTI!NNRTI 22/533 4.4 (3.0–5.8)
PI 1/533 0.1 (0.01–0.2)
HIVDR among VFs
any 28/30 96.1 (72.9–99.6)b
NRTI 23/30 90.3 (65.6–97.9)b
NNRTI 26/30 94.1 (74.3–98.9)b
NRTI!NNRTI 22/30 89.5 (64.7–97.5)b
PI 1/30 1.1 (0.14–3.6)
aAll prevalences are weighted and accounted for the two-stage clus-
tered survey design.
bLog-transformed CI.
cOne missing age.
Table 3. Independent factors associated with virological failure among the 40 ADR12 participants in Uganda
Univariate analysis Multivariate analysisa
Characteristics VL 1000 copies/mL, n (%)b crude OR (95% CI) P value adjusted OR (95% CI) P value
Gender
male 13 (7.1) 1 1
female 27 (7.7) 2.87 (0.69–11.79) 0.14 7.36 (0.84–644.7) 0.33
Age
34 years 20 (7.0) 1 1
<34 years 20 (8.2) 1.08 (0.26–4.54) 0.91 0.21 (0.00–22.32) 0.46
Region 0.002
Central 13 (8.0) 1 1
East 10 (14.7) 1.61 (0.43–5.96) 0.46 1.06 (0.26–4.33) 0.91
Kampala 4 (11.8) 2.35 (1.41–3.91) 0.002 – –
North 3 (3.2) 1.17 (0.43–3.17) 0.74 1.25 (0.69–2.27) 0.40
West 10 (5.7) 0.76 (0.37–1.53) 0.42 0.97 (0.03–34.95) 0.99
CD4 count at ART initiationc
250 cells/mm3 7 (5.6) 1 1
<250 cells/mm3 12 (15.8) 3.85 (0.67–22.14) 0.11 0.99 (0.99–1.00) 0.18
Initial ART regimen 0.72
TDF!3TC!EFV/NVP 34 (7.8) 1
ZDV!3TC!EFV/NVP 5 (8.6) 0.82 (0.19–3.49) 0.77
TDF!FTC!EFV 1 (2.6) 2.18 (0.31–15.40) 0.41
aAge and gender were added to the multivariate model to control for confounding.
bFourteen patients whose VL did not amplify were not included in the analysis.
cCD4 counts of 21 patients were missing.
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Table 4. Predictors of HIVDR in the 28 ADR12 participants receiving ART in Uganda
Univariate analysis Multivariate analysisa
Characteristics HIVDRMs, n (%) crude OR (95% CI) P value adjusted OR (95% CI) P value
Gender
male 8 (4.4) 1 1
female 20 (5.7) 2.15 (0.31–14.75) 0.41 8.34 (0.04–1839.12) 0.38
Age
34 years 15 (5.2) 1 1
<34 years 13 (5.3) 0.79 (0.16–3.78) 0.91 0.07 (0.00–8.20) 0.23
Region 0.002
Central 10 (6.2) 1 1
East 8 (11.8) 0.96 (0.08–11.27) 0.97 0.34 (0.01–19.35) 0.55
Kampala 4 (11.8) 2.36 (1.42–3.91) 0.002 – –
North 2 (2.2) 1.14 (0.42–3.10) 0.74 1.36 (0.65–2.83) 0.35
West 4 (2.3) 0.65 (0.28–1.49) 0.29 1.14 (0.00–356.92) 0.96
CD4 count at ART initiation
250 cells/mm3 2 (1.6) 1 1
<250 cells/mm3 11 (14.5) 15.35 (1.08–218.28) 0.05 30.6 (0.28–3386.92) 0.13
Initial ART regimen 0.72
TDF!3TC!EFV/NVP 24 (5.5) 1
ZDV!3TC!EFV/NVP 3 (5.2) 0.46 (0.07–3.25) 0.42
TDF!FTC!EFV 1 (2.6) 2.34 (0.32–16.96) 0.38
Fourteen patients whose VL did not amplify and 10 with failed genotyping were not included in the analysis. CD4 counts of 15 patients were missing.
aAge and gender were added to the multivariate model to control for confounding.
Table 5. Demographic, clinical and immunological characteristics of the
1064 ADR48 participants in Uganda
Characteristics Total
Gender, n (%)
male 369 (34.7)
female 695 (65.3)
Age, years, median (IQR) 44 (37-51)
Region, n (%)
Central 230 (21.6)
Eastern 184 (17.3)
Kampala 138 (13.0)
Northern 230 (21.6)
Western 282 (26.5)
CD4 count at ART initiation, cells/mm3, median (IQR) 214 (126–310)
Viral load, n (%)
<1000 copies/mL 926 (87.0)
1000 copies/mL 138 (13.0)
VL among VFs, log10 copies/mL, median (IQR) 3.7 (3.6–3.9)
Time on ART, months, median (IQR) 82.0 (78.5–85.0)
Initial ART regimen, n (%)
ZDV!3TC!EFV/NVP 658 (61.8)
TDF!3TC!EFV/NVP 305 (28.7)
D4T!3TC!EFV/NVP 101 (9.5)
Table 6. Weighted prevalencea of virological suppression and HIVDR
among ADR48 participants
Survey outcome n/N Percentage prevalence (95% CI)
VL suppression
all 926/1064 87.9 (85.0–90.9)
male 319/369 87.5 (83.0–92.2)
female 607/695 88.2 (85.3–91.0)
age <44 years 453/530 87.1 (83.7–90.5)
age 44 years 473/534 88.7 (84.8–92.6)
HIVDR
any 88/1064 7.6 (5.4–9.5)
NRTI 84/1064 7.3 (5.2–9.5)
NNRTI 86/1064 7.4 (5.1–9.7)
NRTI!NNRTI 81/1064 7.0 (4.9–9.1)
HIVDR among VFs
any 88/95 90.4 (73.6–96.8)b
NRTI 84/95 86.8 (76.3–97.3)
NNRTI 86/95 87.6 (76.4–98.8)
NRTI!NNRTI 82/95 81.9 (71.2–92.6)
aAll prevalences are weighted and accounted for the two-stage clus-
tered survey design.
bLog-transformed CI.
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facility.11 Although we did not find any factors associated with VF
among the ADR12 patients, the ADR48 patients on ART for more
than 82 months and who initiated on a zidovudine-based regimen
compared with a tenofovir-based regimen were most likely to
have VF. In contrast, under the Uganda national VL programme,
VF was associated with young age, poor adherence and having
active tuberculosis.22
In this study, although the VLS rates were high, we found that
almost all participants that had VF and were genotyped had DRMs.
The high HIVDR among those failing first-line therapy suggests
that failure should be followed by an immediate switch since
the recommended PI-based second-line or dolutegravir-based
regimens currently have minimal resistance levels. The current
recommendation of three intensive adherence counselling (IAC)
sessions 1 month apart followed by repeat VL testing on the third
IAC visit prior to treatment switch urgently needs to be reviewed
especially since IAC would not be beneficial to the majority of VFs
in this study. A recent report in Uganda has shown very low VLS
rates (23%) following IAC among children and adolescents, of
whom only 50% had completed the three IAC sessions23 and,
among adults, close to 70% do not return for their scheduled se-
cond VL test according to the national VL programme (unpub-
lished results). A study in Uganda and Zimbabwe among children
receiving long-term ART without routine VL monitoring showed
that among children who were retrospectively tested and found
with viral rebound, none had re-suppressed, which demonstrated
the limited utility of IAC among these children.24 From other
selected cross-sectional surveys from South Africa among adults
with VF on the first VL, very high levels of HIVDRMs were shown be-
tween 2010 and 2012 (86%)25 and in 2013 (89%).26 The immedi-
ate switching of unsuppressed individuals avoids keeping them on
failing regimens with the potential to transmit HIVDR. These, along
with our findings, should prompt an urgent review of the IAC
approach.
The risk of VF and HIVDR at 48 months is almost comparable to
that at 12 months, implying that adherence support and retention
in care initiatives are beneficial. The first-line regimens used by
study participants that developed the highest resistance are in the
process of being phased out as the country optimizes regimens to
shift to a dolutegravir (DTG)-based regimen. The recommendation
by WHO for change of regimen to TDF!3TC!DTG was due to the
high pre-treatment drug resistance to NNRTIs, better tolerability,
superior efficacy and higher genetic barrier of dolutegravir. There
were earlier dolutegravir safety concerns reported among women
of reproductive potential in Botswana showing that 0.9% (4/426)
of babies whose mothers became pregnant while taking dolute-
gravir had a neural tube defect compared with 0.1% (14/11 173)
of babies whose mothers were on other regimens.27,28 However,
recent results have not shown a clear link of dolutegravir to neural
tube defects29,30 and subsequently the WHO has updated the
Table 7. Independent factors associated with virological failure among the 138 ADR48 participants in Uganda
Univariate analysis Multivariate analysisa
Characteristics VL 1000 copies/mL, n (%) crude OR (95% CI) P value adjusted OR (95% CI) P value
Gender
female 88 (12.7) 1 1
male 50 (13.6) 1.07 (0.73–1.57) 0.73 0.96 (0.67–1.34) 0.79
Age
44 years 61 (11.4) 1 1
<44 years 77 (14.5) 1.16 (0.77–1.75) 0.45 1.05 (0.68–1.62) 0.80
Region 0.84
Central 33 (14.4) 1
East 26 (14.1) 1.24 (0.49–3.15) 0.63
Kampala 19 (13.8) 1.25 (0.59–2.67) 0.54
North 30 (13.0) 1.07 (0.44–2.60) 0.88
West 30 (10.6) 0.87 (0.43–1.77) 0.69
CD4 count at ART initiationb
<250 cells/mm3 76 (13.6) 1
250 cells/mm3 43 (11.8) 0.83 (0.50–1.34) 0.50
Time on ART
<82 months 55 (11.0) 1 1
82 months 81 (14.9) 1.45 (0.89–2.36) 0.12 1.77 (0.94–3.33) 0.07
Initial ART regimen 0.37
TDF!3TC!EFV/NVP 32 (10.5) 1 1
ZDV!3TC!EFV/NVP 97 (14.7) 1.45 (0.81–2.63) 0.20 1.96 (1.13–3.39) 0.02c
D4T!3TC!EFV/NVP 9 (8.9) 0.97 (0.48–1.96) 0.91 1.70 (0.66–4.37) 0.25
aAge and gender were added to the multivariate model to control for confounding.
bNineteen patients had missing CD4 counts, and two patients had time on ART missing.
cStatistically significant (P < 0.05).
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treatment guidelines that include the use of dolutegravir in chil-
dren and adults including pregnant women for first- and second-
line regimens.31 The WHO has further recommended increased
surveillance to definitively confirm the effect of dolutegravir on
neural tube defects and to provide information about the risks and
benefits of dolutegravir for childbearing women in order to make
informed choices.
Our study did have some limitations that were mainly technical
and included the genotyping and VL testing failures that could
possibly be attributed to the use of DBS samples. In resource-limited
settings, DBS has been validated and recommended for HIVDR
surveillance surveys due to its cost effectiveness and ease of
transportation;16,32 however, it has some limitations compared with
testing of plasma. The PCR efficiency of DBS is reduced when VLs are
<5000 copies/mL, and the RNA integrity is further affected by sample
quality due to poor blood collection techniques, and DBS preparation,
transportation and storage. The use of DBS for VL quantification has
been shown to present some false-positive results due to proviral
DNA contamination at low VL copies,33 and this may lead to an
overestimation of VF and underestimation of ADR.
The DBS samples used in this study were collected and
transported to our lab using the routine National Sample and
Results Transport Network.17 The overall genotyping success rate
was 69.1%; however, among the samples that failed genotyping,
75% had a VL between 1000 and 5000 copies/mL while those with
VL >5000 copies/mL had success rates of 87% (Table S3).
Results from this study that have demonstrated high
VLS rates but very high HIVDR among patients with VF
should be of concern with regard to onward transmission of
HIVDR. The WHO has recommended roll-out of dolutegravir,
a drug with a high genetic barrier to drug resistance, and
this should be coupled with baseline surveys among patients
initiating or switching to dolutegravir-based regimens to
estimate the prevalence and profile of HIVDRMs to integrase
inhibitors.
Conclusions
While VLS was generally good among individuals on first-line ART
at 12 and 48 months, we found a high prevalence of ADR among
the VFs before they underwent the recommended IAC. The three
IAC sessions 1 month apart followed by repeat VL on the third IAC
may be of limited benefit in improving VLS, and the delayed
switching may increase the risk of HIV transmission and accumula-
tion of DRMs, thus further compromising the effectiveness of the
second-line regimens.
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